Pipeline

Two in-licensed programs.

Multi-specific antibody programs in oncology — each on the same eight-to-sixteen-week path from sequence to in-vitro PoC; in-vivo schedule partner-lab dependent.

NOVA-3 · P1 — IMT030122

EpCAM × CD3 × 4-1BB
trispecific TCE

EpCAM-positive epithelial tumors. Tumor-targeted T-cell engagement with 4-1BB costimulation to mitigate T-cell exhaustion associated with sustained CD3 engagement (mechanism requires validation). In-licensed program.

EpCAM — tumor targeting
CD3ε — TCR engagement
4-1BB — costimulation gate
In silico PoC In-licensed · Sch. B
NOVA-3 · P2 — IMB030202

EpCAM × 4-1BB × HSA

EpCAM-positive epithelial tumors. Tumor-localized 4-1BB costimulation (no CD3) designed to concentrate agonism in EpCAM-positive tissue while limiting systemic exposure; a human serum albumin (HSA) module extends half-life. Mechanism requires validation. In-licensed program.

EpCAM — tumor targeting
4-1BB — conditional costimulation
HSA — half-life extension
In vitro PoC In-licensed · Sch. B
Workflow · the DBTL loop

Sequence to PoC in 8–16 weeks.

The same design–build–test–learn path runs under every program. Wet-lab results feed back into the Module Library, so each cycle starts from a stronger corpus. In-vivo schedule is partner-lab dependent.

Eight-to-sixteen-week DBTL timeline: Design, Build, Test, Learn, with a flywheel feeding the Learn stage back to the Module Library. DBTL FLYWHEEL · LEARN → MODULE LIBRARY wk 0 wk 4 wk 6 wk 12 wk 16 DESIGN Generate & rank top-24 · NOVA-Compute BUILD Gene synthesis & expression TEST SPR · BLI · ADCC dose-response LEARN In-vitro PoC · evidence bundle
Figure — DBTL cycle. Indicative durations from target intake to in-vitro proof-of-concept; in-vivo efficacy work runs on the partner lab’s schedule. Each completed cycle re-trains the Module Library.
The DBTL flywheel Design · Build · Test · Learn — each cycle compounds the corpus continuous loop · clockwise schematic — not measured data D DESIGN generate candidates B BUILD express / assemble T TEST wet-lab assays · SPR / BLI / ADCC L LEARN assay results re-train corpus Module Library compounds every cycle +~0.8% accuracy / program / cycle (internal target — not a measured result) arc thickness grows toward LEARN→DESIGN — momentum carried back into the next design cycle
Figure — The DBTL flywheel. Each program turns the same loop: DESIGN generates candidates, BUILD expresses and assembles them, TEST runs wet-lab SPR / BLI / ADCC assays, and LEARN folds the results back into the Module Library so the next cycle starts from a stronger corpus. The compounding rate shown (+~0.8% accuracy / program / cycle) is an internal target, not measured data.
Program detail · numbers

Where each program stands.

The pipeline today — all figures below are in-silico predictions and design targets; wet-lab validation is scheduled, not yet complete, and is labelled as such. P2 is the most advanced (in-vitro); P1 leads on clinical-relevance scope.

Program pipeline stage chart: two active programs (P1, P2) plotted across five sequential development stages. Solid copper, verdigris and sodium bars mark completed stages up to each program's honest current stage; dashed grey segments mark planned future stages not yet started. A vertical TODAY marker separates completed from planned work; no program shows in-vivo or clinical data. PROGRAM PIPELINE · HONEST STAGE OF EVIDENCE internal status · pre-partnered · no clinical data DESIGN IN-SILICO PoC IN-VITRO PoC IN-VIVO PoC IND-ENABLING TODAY P1 EpCAM × CD3 × 4-1BB trispecific TCE · IMT030122 current: In-silico PoC (computational only) P2 EpCAM × 4-1BB × HSA tumor 4-1BB · IMB030202 current: In-vitro PoC (binding / cell assays) solid = completed dashed = planned / not yet TODAY marker no in-vivo or clinical data claimed
Figure — Program stages. Honest current stage of evidence for two active programs across five sequential development stages. Solid bars mark completed stages; dashed grey segments are planned, not-yet-started work, and the TODAY line marks the furthest any program has reached — no program shows in-vivo or clinical data.
P1
In silico PoC

P1 · Trispecific TCE with conditional costimulation

EpCAM tumor targeting × attenuated CD3 × 4-1BB conditional agonism. The third arm is a costimulation gate designed to concentrate agonism in the tumor microenvironment — designed to mitigate T-cell exhaustion from sustained CD3 engagement; conditional costimulation mechanism requires in-vitro and in-vivo functional validation. Lead candidate assembled from validated EpCAM, CD3, and 4-1BB modules.

Predicted Kd (EpCAM)
design target
Structural conf
in progress
Wet-lab status
Scheduled Q3 '26
IP status
In-licensed · Sch. B
P2
In vitro PoC

P2 · Tumor-localized 4-1BB costimulator

EpCAM tumor targeting × 4-1BB conditional costimulation × HSA half-life extension. Tumor-localized 4-1BB agonism designed to concentrate costimulation in EpCAM-positive tissue while limiting systemic exposure; the HSA module extends serum half-life. No CD3 arm. Mechanism requires in-vitro and in-vivo functional validation. Cargo-agnostic scaffold.

Target Kd (EpCAM)
design target
Format
EpCAM × 4-1BB × HSA
In vivo
Q3 '26
IP status
In-licensed · Sch. B
Full case studies → Partner with us